To the best of our knowledge, this is the only confirmatory study that aims to establish a less toxic alternative to taxanes to be combined with double blockade of HER2 with Tmab and Pmab for HER2+ breast cancer in the advanced-disease setting. This evidence concerns the gene ERBB2 and breast cancer.